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Abstract
CMV status is an important risk factor in immune compromised patients. In hematopoeitic cell transplantations (HCT), both
donor and recipient are tested routinely for CMV status by serological assays; however, one might argue that it might also
be of relevance to examine CMV status by cellular (i.e., T lymphocyte) assays. Here, we have analyzed the CMV status of 100
healthy blood bank donors using both serology and cellular assays. About half (56%) were found to be CMV seropositive,
and they all mounted strong CD8+ and/or moderate CD4+ T cell responses ex vivo against the immunodominant CMV
protein, pp65. Of the 44 seronegative donors, only five (11%) mounted ex vivo T cell responses; surprisingly, 33 (75%)
mounted strong CD4+ T cell responses after a brief in vitro peptide stimulation culture. This may have significant
implications for the analysis and selection of HCT donors.
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Introduction
Human cytomegalovirus (CMV) is a ubiquitous b-herpes virus
infecting 50–80% of the adult population [1,2]. It rarely causes
disease in immunocompetent individuals; rather, CMV establishes
a life-long asymptomatic latent infection with intermittent sub-
clinical reactivations, which are controlled by the immune system.
In immunocompromised patients, however, reactivation of CMV
can cause considerable morbidity and mortality especially after
solid organ transplantation and allogeneic hematopoietic cell
transplantation (HCT) [3,4,5,6]. The risk and outcome of CMV
reactivation is a particularly complicated issue in HCT due to the
gross disturbance of the otherwise finely tuned balance between
the viral burden (contributed by latent infections of either the
recipient and/or the donor graft) and the immune system
(suppressed and destined to be replaced by the donor immune
system, which may or may not be CMV experienced). Reestab-
lishing appropriate immune control of latent CMV infection
depends upon the CMV statuses of the donor and the recipient [7]
and strongly affects the outcome of the HCT [4,8,9].
Prior to implementation of effective anti-CMV drugs in the
early 1990s, CMV disease (often presenting itself as CMV
pneumonitis) used to be the leading infectious cause of death
among CMV-seropositive recipients of HCT [4]. The implemen-
tation of preventive strategies encompassing prophylaxis and
preemptive therapy [10] has reduced CMV disease during the first
3 months after HCT from 20–30% to less than 5% [10]. Despite
of these accomplishments, establishing the CMV statuses of the
HCT recipient and of the donor are still of considerable prognostic
value for CMV reactivation and the outcome of HCT.
The CMV statuses of donor and recipient prior to HCT are
routinely determined by serological testing for CMV-specific IgG
and/or IgM antibodies [11]. However, CMV-specific T cells may
be more important for immune protection against CMV
reactivation and for long-term control of the virus [12,13,14,15].
Thus, CMV reactivation occurs particularly frequently in
seropositive HCT-recipients of T cell depleted grafts which often
become refractory to antiviral therapy [4,16,17], and adoptive
transfer of CMV-specific CD4+ and/or CD8+ positive T cells
affords protection against CMV [18,19,20,21]. Thus, establishing
whether the donor is capable of raising a cellular response against
CMV might be of considerable prognostic value.
Here, we have analyzed the CMV status of 100 healthy blood
donors using a standard ELISA-driven serology test and in parallel
a cellular test measuring intracellular cytokine secretion (ICS) in
CMV-specific T cells.
Results
Establishing CMV status by serology
A commercial ELISA-based kit was used to determine total
anti-CMV IgG and IgM antibodies in donor plasma of 100
anonymous healthy blood donors, aged 19 to 75. Of these 100
donors, 44 were CMV seronegative and 56 were CMV
seropositive. There was a slightly lower median age distribution
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31420in the seronegative group (33.5 years) than in the seropositive
group (40.5 years) (not significant, P=0.15).
Cellular CMV reactivity in seropositive or seronegative
individuals
In general, antibodies recognize antigen structures. In contrast,
T cells always recognize short peptide fragments derived from
protein antigens and presented in the context of the highly
polymorphic MHC molecules on the surface of antigen presenting
cells. The blood donors were tested for the presence of CMV-
specific T cell responses. Mixtures of overlapping peptides, e.g. 15
amino acid long peptides overlapping by 11 amino acids, may
conveniently represent protein antigens. This peptide size and
overlap optimize the chances of simultaneously generating both
the longer (about 13 amino acid) CD4 T cell targets and the
shorter (about 9 amino acid) CD8 T cell targets during the cell
culture [22,23]. As target protein we selected the CMV lower
matrix phosphoprotein 65, pp65. It is one of the most highly
expressed CMV proteins, and it is also one of the most dominant
CD4 and CD8 T cell antigen derived from CMV [14].
T cells stimulated with overlapping pp65 peptide mixtures were
analyzed by ICS to determine the phenotype (CD4 versus CD8),
activation status (CD69) and functionality (IFNc and TNFa
secretion) of the responding T cells. Due to the intermittent
reactivation of the latent CMV infection, CMV-specific T cells can
be found in sufficiently high frequencies (at least for some epitopes)
to enable direct ex vivo detection. However, to assure that any low
frequency T cell responses were not missed, pp65 specific T cell
responses were analyzed both ex vivo and after a brief in vitro
stimulation culture. Examples of the ICS analysis ex vivo and after
in vitro stimulation of a seronegative and of a seropositive donor are
shown in Figure 1A. The seropositive donor of the example
exhibited ex vivo CMV-specific CD4 and CD8 T cell responses,
whereas the seronegative donor of the example only exhibited
CD4 T cell responses after in vitro stimulation. The frequency data
of all 100 donors is shown in Figure 1B (ex vivo responses) and
Figure 1C (after in vitro stimulation). It is readily apparent that the
vast majority of seropositive donors gave strong ex vivo CD4 and/
or CD8 T cell responses, and this was even more pronounced after
in vitro stimulation. In contrast, the vast majority of the
seronegative donors gave no ex vivo CD4 and/or CD8 T cell
responses. Surprisingly, 33 (75%) of the 44 seronegative donors
gave a strong pp65 specific CD4 T cell response after in vitro
stimulation.
A more detailed analysis of the ex vivo T cell responses (Table 1)
showed that 56 (100%) of the 56 CMV seropositive donors
exhibited ex vivo cellular responses against CMV pp65: 34 (61%) of
the 56 seropositive donors gave both CD4 and CD8 T cell
responses, 6 (11%) exhibited a CD4 T cell response only, and 16
(28%) exhibited a CD8 T cell response only. In contrast, only 5
(11%) of the 44 seronegative donors exhibited ex vivo cellular
responses against CMV pp65: one donor gave both CD4 and CD8
T cell responses, two gave a CD4 T cell response only, and two
gave a CD8 T cell response only. In 39 (89%) of the 44
seronegative donors, no ex vivo pp65-specific T cell responses
could be detected.
This picture changed considerably when the cells were briefly in
vitro stimulated with a mixture of overlapping CMV pp65 peptides
(Table 2). As before, all seropositive donors gave pp65 specific T
cell response, albeit even stronger responses than ex vivo. Thus, all
seropositive donors now gave detectable CD8 T cell responses,
and as much as 47 (84%) of the 56 seropositive donors gave both
CD4 and CD8 T cell responses. The most dramatic change,
however, was observed for the seronegative donors: whereas only 5
(11%) of the 44 seronegative donors had exhibited pp65-specific T
cell responses ex vivo, 34 (77%) of the same 44 seronegative donors
exhibited pp65-specific T cell responses after pp65 peptide
stimulation. This peptide stimulation T cell response was in
particular driven by CD4 T cells: 33 (75%) of the 44 seronegative
donors exhibited strong CD4 T cell response after peptide
stimulation, 10 of these had also a CD8 T cell response, and
only one of the 44 seronegative donors exhibited solely a CD8 T
cell response after pp65 peptide stimulation.
Thus, pp65-specific CD4 T cell responses dominated in the
stimulated seronegative donor PBMC’s. This was in clear contrast
to the seropositive donors where CD8 T cell responses dominated,
both in frequency of donors responding and in terms of
frequencies of specific T cells within the individual donor. This
picture of an apparent dichotomy of CD4 and CD8 T cell
responses in seronegative and seropositive individuals, respectively,
was reinforced when considering the strength of the responses.
The average frequency of specific T cells in the donors giving a
detectable CD8 T cell response after in vitro stimulation was much
higher in the seropositive than in the seronegative group (20,3%
(range 0.6–87%) vs. 1.5% (range 0.3–9.8%), respectively,
Figure 1B). In contrast, the CD4 responses in both groups were
comparable after a in vitro stimulation culture (4,4% (range 0.4–
46%) vs. 4.5% (range 0.3–11.4%), Figure 1C). Thus, seropositive
individuals tended to give CD8 T cell responses, whereas
seronegative individuals tended to give a CD4 T cell responses
both in terms of frequency of donors responding and in terms of
frequencies of specific T cells within the individual donors.
Discussion
We have examined CMV serology and CMV pp65-specific T
cell responses in 100 healthy blood bank donors. An established
ELISA-driven assay was used to determine total anti-CMV IgG
and IgM antibodies, and thereby the serological CMV status. This
showed that about half (56%) of these donors were seropositive.
Others have made similar findings [2], although variations can be
considerable depending on several factors such as age, sex,
ethnicity and socio-economic factors [24]. These donors were then
examined for CD4 and CD8 T cell responses specific for a peptide
mixture representing the immunodominant CMV protein, pp65,
both measured ex vivo and after a brief in vitro stimulation
culture. A very strong positive correlation was found between
serology and ex vivo T cell responses defined as either a CD4 or a
CD8 T cell response. By this token, every seropositive donor was
identified by the cellular analysis, whereas only 5 (11%) of the
seronegatives were identified (these could be categorized as false
positives). Sester et al. observed similar strong concordance in a
study where serology was compared to CD4 T cell responses using
a CMV lysate as antigen preparation [25]. Whereas Sester et al.
found that 100% of the seropositives gave ex vivo CD4 T cell
responses to a CMV lysate, we found that 71% of the seropositives
gave ex vivo CD4 T cell responses to a mixture of pp65 peptides.
Partly explaining this difference is the fact that the pp65 protein,
albeit being immunodominant, is only one of the more than 150
proteins, which have been shown to be immunogenic for CD4+
and/or CD8+ T cells [14]. Indeed, CMV lysates yield stronger
CD4 T cell responses than mixture of pp65 peptides (unpublished
observation). Sester et al. found that the few cases of false positives
could be resolved by repeating the serological analysis whereby the
seronegative assignment could be changed to seropositive
suggesting that the T cell approach might actually be slightly
more reliable that the serological approach. In contrast, our
serological assignment remained unaltered when we repeated the
T Cell Assay of CMV in Healthy Donors
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31420serological analysis of the seronegative donors (data not shown).
The major advantage of using the pp65 peptide mixture compared
to a lysate is that it allows CD4 and CD8 T cell responses to be
examined in parallel, something that Sester et al. could not do.
Others have also successfully used pp65 derived peptide mixtures
to examine CMV-specific CD8 T cell responses [26,27].
Figure 1. Detection of pp65 specific CD4+ and CD8+ T cell responses. PBMC from 100 healthy donors, 44 CMV seronegative and 56
seropositive, were analyzed either ex vivo or after in vitro stimulation with the pp65 peptide mixture for 7 days. The cells were examined for pp65
specific responses using the ICS assay and stained for CD4, CD8, CD69 and intracellular TNFa and IFNc collectively. Background activation obtained in
the absence of peptide was subtracted from the results obtained with the peptide mixture. In A) is shown examples of the ICS analysis of CD4 and
CD8 T cell responses measures ex vivo and after stimulation of both a seropositive and a seronegative donor. In B) the ex vivo measured frequency of
pp65 specific CD4 and CD8 T cells is shown for each seronegative and seropositive donor, respectively. In C) the frequency of pp65 specific CD4+ and
CD8+ T cells measured after in vitro stimulation is shown for each seronegative and seropositive donor, respectively. After in vitro stimulation, the
background activation was slightly higher than observed ex vivo; positive responses were defined as frequencies .0.09% for the ex vivo analysis, and
as frequencies .0.3% for the in vitro stimulation analysis. Background frequencies have been subtracted the specific frequencies and responses
above 0.09% for the ex vivo analysis and 0.3% for the in vitro analysis were considered positive. Shown as the responses above the grey areas.
doi:10.1371/journal.pone.0031420.g001
Table 1. Ex vivo responses.
Seronegative individuals Seropositive individuals
Ex vivo responses # % # %
No T cell responses 39 89 0 0
CD4 T cell responses only 2 4.5 6 11
CD8 T cell responses only 2 4.5 16 28
Both CD4 and CD8 T cell responses 1 2 34 61
Total 44 100 56 100
doi:10.1371/journal.pone.0031420.t001
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(<75%) of seronegative donors that can mount a pp65-reactive
CD4 T cells response after a brief in vitro stimulation culture. One
explanation of this seeming anomaly might be that the observed
CD4 T cell responses are not due to the immune system being
bona fide CMV experienced, but rather due to immune cross-
reactions to one or more of the closely related herpes virus.
Partially addressing this question, we analyzed the CD4 T cell
responses towards a lysate of HHV6 virus (Advanced Biotechnol-
ogies Inc.). In no case did the CD4 T cell responses of the in vitro
pp65 stimulated seronegative T cells respond to the HHV6 lysate,
although they all responded to a CMV lysate (data not shown).
This does not rule out that these CD4 T cell responses are the
result of cross-reactions against other related infectious agents and
it remains a possible explanation for the observed CD4 T cell
responses. In this context it should be noted that antigenic cross-
reactivity has been observed between related herpes virus
[28,29,30] and between related flavivirus [31,32].
An alternative explanation for these findings could be that the in
vitro peptide stimulation protocol has led to in vitro priming. We
consider that unlikely since this would have required the presence
of mature dendritic cells (DC’s) [33,34,35,36,37,38,39]. PBMC’s
do not contain sufficient numbers of DC’s to support in vitro
priming. In fact, PBMC are noted for their ‘‘inability to support
the sensitization of naı ¨ve antigen-specific lymphocytes under
nearly all experimental conditions’’ [40]. Moreover, to avoid the
risk of in vitro priming of naı ¨ve antigen-specific T cells, our in vitro
expansion culture of non-adherent cells have on purpose been
depleted of DC’s. Rather, we separate DC and T cells allowing us
to expand and mature a DC population in the absence of specific
peptides, and to expand any specific memory T cell population in
the presence of specific peptides. At the time of testing, the DC’s
are pulsed with specific peptides and only then mixed with the
expanded T cells (the entire protocol is illustrated in Figure 2).
Thus, our protocol is designed to minimize the risk that specific
peptide, DC and T cells should all be present at the same time
during the 7 day maturation and expansion period. To
experimentally exclude that this in vitro stimulation procedure
could lead to in vitro priming of pp65-specific CD4 T cell
responses, five healthy donors were analyzed for responses against
peptide mixtures derived from Yellow Fever virus. Since this virus
is not endemic in our part of the world and the donors had never
been vaccinated against Yellow Fever, we expected the immune
system of our donors to be naı ¨ve with respect to Yellow Fever.
None of the five naı ¨ve donors gave either CD4 or CD8 T cell
responses against Yellow Fever derived peptides (data not shown).
We conclude that the in vitro stimulation protocol used here is
unable to perform in vitro priming.
Another alternative explanation might be that the classical
serology criteria of CMV-experience could be skewed by the
phenomenon of maternal antibody interference, in which specific
maternal antibodies inhibits the development of specific antibody
responses, but not that of T cell responses (see Text S1 for
supplementary discussion of this phenomenon). This could affect
the outcome of primary immunity against CMV-infections of the
newborn and could potentially explain the very high frequency of
CD4+ T cell responses in the absence of a humoral anti-CMV
response. This scenario, however, raises other enigmas e.g. why
would CMV reactivation and seroconversion in these individuals
not have occurred later in life?
Table 2. In vitro stimulated responses.
Seronegative individuals Seropositive individuals
In vitro stimulated responses # % # %
No T cell responses 10 23 0 0
CD4 T cell responses only 23 52 0 0
CD8 T cell responses only 1 2 9 16
Both CD4 and CD8 T cell responses 10 23 47 84
Total 44 100 56 100
doi:10.1371/journal.pone.0031420.t002
Figure 2. Flow diagram of the cell analysis. At day 1, some PBMC’s
were use directly for an ex vivo analysis of pp65 specific T cells. The
remaining PBMC’s were split in adherent and non-adherent cells. The
non-adherent cells comprising the T cells were expanded on a pp65
peptide mixture. The peptide mixture was added overnight, washed
away the next day, and the T cells were propagated on IL2 until day 7.
At the same time, the adherent cells were cultured for 7 days in the
presence of IL4 and GM-CSF to mature the into DC. At day 7, both the T
cells and the DC’s were harvested. The DC’s were pulsed with the pp65
peptide mixture and added to the T cells (at the ratio 1:10) during a 4 h
ICS assay.
doi:10.1371/journal.pone.0031420.g002
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seronegative individuals may have some important prognostic
implications for the selection of HCT donors and for the outcome
of HCT. Seronegative donors, who mount an anti-pp65-specific,
CD4+ T cell response (irrespective of how these have been
generated), may be capable of mediating immune protection
against CMV disease in the HCT recipient. CD4 T cells are
known to be important for the control of CMV infection and
reactivation. In healthy primary infected individuals, CD4 T cell
responses precede antibody and CD8 T cell responses [41]. In
HCT patients, CMV reactivation correlates with absence of
CMV-specific CD4 T cells [3,41,42,43,44]. Transfer studies have
shown that transfer of specific CD4 T cells can protect against
CMV reactivation and disease [19], and specific CD8 T cells can
clear an ongoing CMV infection, but not establish lasting
immunity [21,45]. Therefore, CMV-reactive CD4 T cells may
contribute to a faster reestablishment of CMV immunity especially
in HCT patients receiving a CMV seronegative donor graft. Thus,
CMV-specific CD4 T cell responses (ex vivo, or after in vitro
stimulation), rather than serology, might be a better risk indicator
of CMV disease in allogeneic transplantations including HCT.
For the CMV-seronegative HCT recipient it may be preferable
to use a CMV-seronegative donor to avoid primary CMV
infection [4]. Intuitively, one would expect the use of a graft from
a seropositive donor to be preferred to a CMV-seropositive
recipient due to the potential for active transferred immunity.
However, the data to support these hypotheses have been
conflicting. CMV-seropositivity in the recipient is clearly associ-
ated with poorer outcome, but in some studies the survival curves
for CMV-seropositive donors versus CMV-seronegative donors
were super imposable for both CMV–positive and –negative
recipients [4]. Our findings of a frequent occurrence of CMV
reactive CD4 T cells in CMV seronegative individuals might
explain these contradictory findings. CMV-seronegative donors,
having highly cross-reactive and readily expandable CD4 T cells,
might quickly be able to initiate competent CMV immunity. In
our study we show that 75% of the seronegative individuals have
CD4 T cells that after a brief in vitro stimulation can be expanded
to high frequencies of up to 10%. Whether there is a correlation
between donors with highly cross-reactive CD4 T cell responses
and protection form CMV reactivation is currently under
investigation.
From a diagnostic point of view, CMV-specific ex vivo T cell
reactivity appears to be a sensitive and specific measure of CMV
status, but in practical terms it does not offer any (at least not yet)
advantages compared to serology. From a prognostic view,
however, CMV-specific T cell reactivity, in particular after in vitro
stimulation, may offer some important advantages. It may identify
HCT donors capable of mounting a CMV-specific T cell response;
donors, that would not have been identified by serology, and
whose graft may afford T cell mediated CMV protection of the
recipient. Thus, establishment of the cellular CMV status of donor
and recipient may be an important criterion in the selection of the
optimal HCT graft and other organ grafts. As the worldwide,
unrelated donor registries continues to increase, the chances of
identifying more than one donor for any given patient increases.
Assessment of T cell mediated anti-CMV reactivity might improve
donor selection and eventually the outcome of HCT.
Materials and Methods
Ethics Statement
The CMV study was approved at the National University
Hospital of Copenhagen by ‘‘The Committees on Biomedical
Research Ethics of the Capital Region’’ (Danish: ‘‘De Videnskab-
setiske Komiteer for Region Hovedstaden’’) (RH-3-CT5604).
Informed written consent was obtained from 100 healthy blood
donors.
The Yellow Fever study was approved at the University of
Copenhagen by ‘‘The Committees on Biomedical Research Ethics
of the Capital Region’’ (Danish: ‘‘De Videnskabsetiske Komiteer
for Region Hovedstaden’’) (H1-2009-095). Informed written
consent was obtained from healthy blood donors.
Peptides
Mixes of 134 peptides (15 amino acids long overlapping by 11
amino acids) spanning the entire CMV pp65 (UniProtKB/Swiss-
Prot entry P06725, 561 amino acids long, 63 kDa) were obtained
from JPT Peptide Technologies GmbH, Germany. For control
purposes, mixes of 150 peptides (15 amino acids long overlapping
by 11 amino acids) spanning parts of the proteome of an
attenuated Yellow Fever vaccine (strain 17D-204) were obtained
from Schafer-N, Copenhagen.
Serological testing
EnzygnostH (Siemens Healthcare Diagnostics, Marburg, Ger-
many, cat # OWGMG13) was used for qualitative detection of
CMV-specific antibodies (total IgM and IgG) in donor plasma.
The ELISA-kit was used according to the manufacturer’s
instructions. Briefly, microtiter plates that have been pre-coated
with inactivated CMV antigen from human cell cultures are
incubated with donor plasma. Bound IgG or IgM are simulta-
neously detected with peroxidase labeled anti-IgG and anti-IgM
antibodies by addition of color substrate and reading by
spectrometry. Results were interpreted as seropositive or seroneg-
ative as per manufacturer’s instructions.
Intracellular cytokine secretion analysis
Peripheral blood mononuclear cells (PBMC) were isolated from
30 ml freshly drawn blood by density gradient centrifugation
(Ficoll-Paque, GE-Healthcare). The ex vivo and the in vitro
stimulation assay strategies are illustrated on the left and right
hand sides, respectively, of Figure 2.
For the ex vivo analysis, 2610
6 freshly isolated PBMC were
stimulated with or without the pp65 peptide mix (2 mg/peptide/
ml) for 6 h at 37uC. Brefeldin A (Sigma Aldrich) was present for
the last 5 h of incubation.
Cells are incubated with 20 mM EDTA for 15 min, washed
and permeablized in 200 ml 1% permeabilizing solution 2 (BD
Biosciences) for 10 min. The cells were then washed and stained
for 45 min at RT with 5 mL monoclonal anti-CD8 allophycocya-
nin (APC)-labelled, 10 mL anti-CD4 peridin chlorophyll protein
(PerCP)-labeled, 10 mL anti-CD69 phycoerythrin (PE)–labeled,
and 10 mL anti-IFNc fluorescein isothiocyanate (FITC)-labeled
and anti-TNFa FITC-labelled (BD PharMingen, San Diego, CA).
Cells were washed with PBS, 1%BSA, 0.01%NaN3 and
subsequently fixed in 1% formalin. The stained cells were
analyzed on a FACS Calibur (BD Biosciences). 5–10*10
3 CD4
and CD8 T cells were acquired.
The remaining PBMC’s of the 30 ml blood sample were setup
in a 7 days in vitro stimulation assay. To assure proper
presentation of both MHC I and II restricted peptides in the
ICS assay after 7 days of stimulation, APC’s were propagated from
the adherent cells while the non-adherent cells containing the T
cells were used for in vitro stimulation (Figure 2). Thus the PBMC
from the 30 ml blood sample were adhered in 24-well plates for
2 h at 37uC, and the adherent cells were cultured for 7 days in
Xvivo15 with 5% AB serum, 100 ng/ml GM-CSF, and 100 ng/
T Cell Assay of CMV in Healthy Donors
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2 mg/ml/peptide pp65 peptide mix in Xvivo15 (Lonza) supple-
mented with 5% autologous serum. To obtain a specific
stimulation with less background expansion the cells were
harvested after 18–20 h incubation washe and plated in new
wells with 50 U/ml IL2. Fresh media and IL2 were added at day
4, and 6. The DC and T cell cultures were harvested at day 7. The
DC’s were pulsed with or without pp65 peptide mix (2 mg/
peptide/ml) for 1 h and then added to the T cells, at a 1:10 ratio of
DC:T cells. The cells were incubated for 4 h at 37uC. Brefeldin A
(SigmaAldrich) was present for the last 3 h of incubation. We find
that extending the incubation for more than 4 h induces
proliferation when analyzing frequencies of specific T cells post
expansion. The cells were then stained and analyzed by flow
cytometry as described above.
The frequency of cytokine producing T cells were determined.
The results are given as frequency of specific cytokine producing T
cells subtracted the background frequency of cytokine producing T
cells in the ‘‘no peptide’’ sample - 0.09% for the ex vivo analysis
and 0.3% for the in vitro stimulated samples. Responses 2 times
above background (thus one time above background for the
subtracted values) were considered positive. All FACS plots were
subsequent evaluated for whether the negative donors by this
definition were truly negative and the positive donors truly
positive. The intensity of the cytokine staining were lower for all
donors with a frequency below 2 times the background level than
for donors above this threshold.
For control purposes, the in vitro stimulation analysis was
repeated on PBMC’s obtained from 5 healthy naı ¨ve donors,
however, substituting the CMV pp65 peptide mixture with similar
peptides mixtures (same sampling strategy (15 amino acid peptide
length, 11 amino acid overlap), similar sampling size (150
peptides/pool) and same peptide concentrations (2 mg/ml/pep-
tide)) derived from the proteome of the Yellow Fever 17D-204
vaccine.
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